Janux Therapeutics

We will be hosting a virtual event on Monday, December 1st at 4:30pm ET to discuss updated Phase 1a and Phase 1b clinical data for JANX007 in #mCRPC. A live analyst Q&A session will follow the formal presentation. For details on how to register for the event, see the press release: https://lnkd.in/gyjPEBR2 #JANX #TCellEngagers #cancer #oncology #immunotherapy #immunomodulator #immunooncology #clinicaltrial #mCRPC #prostatecancer

Janux is proud to share that we’ve been recognized as a 2025 Deloitte Technology Fast 500 award winner. Recognition is meaningful to us when it tracks to patient impact. With two drug candidates in clinical trials and more on the way, our progress comes from our great team and how we work: patient centered and science driven with integrity, collaboration, urgency and commitment at every step. See the list for more: https://lnkd.in/gYNYrpnx    #Fast500 #JANX #TCellEngagers #cancer #oncology #autoimmunedisease

Today we reported our third quarter 2025 financial results and business highlights. Janux continues to advance its broad pipeline of novel immunotherapies built on our proprietary TRACTr, TRACIr, and ARM platforms. Enrollment is ongoing in our Phase 1 trials of JANX007 in metastatic castration-resistant prostate cancer and JANX008 in advanced solid tumors, with updates on both programs expected in the fourth quarter of 2025. We are also progressing additional TRACTr, TRACIr, and ARM candidates toward clinical development, including programs designed to expand the reach of our tumor-activated and adaptive immune response platforms. Read the press release for more: https://lnkd.in/g_2YiESa    #Q3Earnings #JANX #TCellEngagers #cancer #oncology #autoimmunedisease

Thank you ZERO Prostate Cancer and #TeamJanux for making the San Diego ZERO Prostate Cancer Run/Walk a success! It was a meaningful way to wrap up Prostate Cancer Awareness Month, and we were proud to support the event again this year as a gold sponsor. At Janux, we’re advancing the fight against prostate cancer with innovative immunotherapies designed to deliver safer, more effective treatments for patients. Together, we’re driving progress in the community and in the clinic toward a future with #ZEROProstateCancer. #GoJanux #PCAM #pcsm #prostatecancer #mCRPC #ProstateCancerAwareness

By valuing ethical practices and clear communication, we ensure that doing the right thing is never in question. That's why integrity is one of our core values at Janux. For Roger Martin, CPA, integrity means fostering trust through honesty and accountability, and he exemplifies this every day in his role as Accounting Manager.    Thank you, Roger, for sharing your insights and inspiring the team! #Culture #CoreValues #LifeAtJanux #integrity #science #oncology #cancer

We were pleased to participate in the Cantor Global Healthcare Conference 2025, where our David Campbell, our President and CEO,  joined Josh Schimmer for a fireside chat. David shared an update on our TRACTr platform and pipeline, including: 🔵  Progress with JANX007, our PSMA-TRACTr in prostate cancer, and upcoming expansion studies. 🔵 The importance of optimizing CRS mitigation strategies while maintaining efficacy. 🔵 Our path forward with next-generation T cell engagers, including the ARM platform in autoimmune disease. David’s conversation with Josh reflected our vision to transform the cancer treatment landscape with tumor-activated T cell engagers that deliver meaningful efficacy while expanding into new areas like autoimmune disease. Listen to the webcast here: https://lnkd.in/gpXTid6V    #JANX #CantorHCC #TRACTr #TCellEngagers #cancer #oncology #autoimmunedisease

Janux has reached a major team milestone!  We now have 100 employees united in our mission to deliver precision-engineered immunotherapies that harness the immune system to transform patients’ lives. It’s more than a number. Our growth reflects the values that define us — integrity, collaboration, and care for one another — and the commitment of every one of us to push the boundaries of science while building a culture where people thrive. #TeamJanux #GoJanux

September is Prostate Cancer Awareness Month — a time to raise awareness about the importance of screening, early detection, and advancing better treatment options. At Janux, we’re committed to developing innovative immunotherapies for prostate cancer, including our PSMA-TRACTr program for metastatic castration-resistant prostate cancer. We’re also proud to support the ZERO Prostate Cancer community and will be walking in the San Diego ZERO Prostate Cancer Run/Walk on October 18 as a gold sponsor. This event brings together patients, families, advocates, and researchers united in the fight to end prostate cancer. 👟 Join us or support the cause: https://lnkd.in/grNcA9ed  📚 Learn more about our work: https://lnkd.in/g7ewWXwB #ProstateCancerAwareness #prostatecancer #mCRPC #ZEROProstateCancer

Thank you Curebound and #TeamJanux for a great #cureboundcancerchallenge! 🚴🏽♀️🏃🏽♀️We're proud to support this event, as we work each day to make a difference in the fight against #cancer. #GoJanux

Today we reported our second quarter 2025 financial results and business highlights. This quarter, we were pleased to showcase the breadth and potential of our TRACTr, TRACIr, and ARM platforms at our inaugural R&D Day. We also continued enrolling patients in our Phase 1 clinical trials for JANX007 and JANX008, each designed to overcome the toxicity limitations of existing T cell engagers, and earned a milestone payment from our Merck collaboration following the first patient dosed in the lead collaboration program. We remain on track to share updated clinical data from JANX007 and JANX008 later this year. Read the press release for more: https://lnkd.in/gHPQXfT5    #Q2Earnings #JANX #TRACTr #TRACIr #TCellEngagers #cancer #oncology